Morningstar says Australian Cochlear's FY27 profit growth target looks "too ambitious"
** Morningstar maintains A$110 fair value estimate on Australia's Cochlear COH.AX
** Investment research firm says the hearing implants maker's new medium-term target of about 10% annual underlying net profit growth is "aggressive" and unlikely to be met
** Co reaffirmed on Friday its FY2027 underlying net profit forecast of A$330 million to A$350 million ($222.78 mln to $236.29 mln)
** Morningstar expects co's revenue and profit to grow at about 5% annually through FY2031
** Estimates current share price of nearly 40% above intrinsic assessment implies revenue growth of about 8% annually for five years and net margin of around 18% versus Morningstar forecasts of about 6% revenue growth and 14% net margin
** 14 of 16 analysts rate the stock "hold" and two "sell"; their median PT is A$138.21, LSEG data
** YTD, stock down 42.1% as of last close
($1 = 1.4813 Australian dollars)